MX387092B - Particulas de dimetilfumarato y composiciones farmaceuticas de estas. - Google Patents
Particulas de dimetilfumarato y composiciones farmaceuticas de estas.Info
- Publication number
- MX387092B MX387092B MX2017016509A MX2017016509A MX387092B MX 387092 B MX387092 B MX 387092B MX 2017016509 A MX2017016509 A MX 2017016509A MX 2017016509 A MX2017016509 A MX 2017016509A MX 387092 B MX387092 B MX 387092B
- Authority
- MX
- Mexico
- Prior art keywords
- particles
- dimethyl fumarate
- dmf
- pharmaceutical compositions
- fumarate particles
- Prior art date
Links
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 title abstract 6
- 229960004419 dimethyl fumarate Drugs 0.000 title abstract 6
- 239000002245 particle Substances 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000002702 enteric coating Substances 0.000 abstract 1
- 238000009505 enteric coating Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562181061P | 2015-06-17 | 2015-06-17 | |
| PCT/US2016/037486 WO2016205270A1 (en) | 2015-06-17 | 2016-06-15 | Dimethyl fumarate particles and pharmaceutical compositions thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017016509A MX2017016509A (es) | 2018-08-16 |
| MX387092B true MX387092B (es) | 2025-03-19 |
Family
ID=56292916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017016509A MX387092B (es) | 2015-06-17 | 2016-06-15 | Particulas de dimetilfumarato y composiciones farmaceuticas de estas. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11291642B2 (enExample) |
| EP (1) | EP3310341A1 (enExample) |
| JP (2) | JP2018517735A (enExample) |
| KR (1) | KR20180018711A (enExample) |
| CN (1) | CN107920997A (enExample) |
| AU (2) | AU2016279997B2 (enExample) |
| CA (1) | CA2989581A1 (enExample) |
| EA (1) | EA201890068A1 (enExample) |
| HK (1) | HK1254054A1 (enExample) |
| IL (1) | IL256296A (enExample) |
| MA (1) | MA42196A (enExample) |
| MX (1) | MX387092B (enExample) |
| WO (1) | WO2016205270A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180318246A1 (en) * | 2015-10-28 | 2018-11-08 | Sun Pharmaceutical Industries Limited | Pharmaceutical compositions of dimethyl fumarate |
| CA3013472A1 (en) * | 2016-02-11 | 2017-08-17 | Biogen Ma Inc. | Pharmaceutical bead formulations comprising dimethyl fumarate |
| EP3691616A1 (en) * | 2017-10-02 | 2020-08-12 | Novartis AG | Method for preparing a pharmaceutical product |
| WO2019194826A1 (en) | 2018-04-06 | 2019-10-10 | Hewlett-Packard Development Company, L.P. | Three-dimensional (3d) object printing based on build material permeability |
| CN113165338B (zh) * | 2018-10-05 | 2023-04-11 | 埃斯普投资有限公司 | 包含水溶性纤维素醚的光滑的高固体膜包衣组合物及其制备工艺 |
| TR201818293A2 (tr) * | 2018-11-30 | 2020-06-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Di̇meti̇l fumarat i̇çeren geci̇kmeli̇ salim sağlayan kapsül |
| AU2020214626B2 (en) * | 2019-01-31 | 2025-10-16 | Halozyme Hypercon, Inc. | Particle formation and morphology |
| CN113840596A (zh) * | 2019-03-20 | 2021-12-24 | 林德拉治疗公司 | 用于胃滞留剂型的衣层 |
| IL286512B2 (en) * | 2019-03-20 | 2026-03-01 | Lyndra Therapeutics Inc | Capsules and capsule coatings for stomach-retaining dosage forms |
| EP4247354A4 (en) * | 2020-11-18 | 2025-02-19 | Fb-Hrs, Llc | COMPOSITIONS CONTAINING DOFETILIDE AND MEXILETINE AND THEIR USES |
| IL303390A (en) | 2020-12-03 | 2023-08-01 | Battelle Memorial Institute | Compositions of polymer nanoparticles and DNA nanostructures and methods for non-viral transport |
| WO2022216977A1 (en) | 2021-04-07 | 2022-10-13 | Batelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
| AU2022285951A1 (en) | 2021-06-04 | 2024-01-04 | Zim Laboratories Limited | Delayed release compositions of dimethyl fumarate |
| US11590071B2 (en) * | 2021-07-06 | 2023-02-28 | King Abdulaziz University | Injectable drug delivery implant composition and method of use thereof |
| WO2025072751A1 (en) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| CN122318997A (zh) * | 2023-10-23 | 2026-06-30 | 埃斯普投资有限公司 | 包封的中链脂肪酸盐及其衍生的口服固体剂型 |
| AU2024393766A1 (en) | 2023-12-08 | 2026-06-18 | Battelle Memorial Institute | Use of dna origami nanostructures for molecular information based data storage systems |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2725623A1 (fr) | 1994-10-18 | 1996-04-19 | Flamel Tech Sa | Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os |
| US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| IL133196A0 (en) | 1999-11-29 | 2001-03-19 | Yissum Res Dev Co | Gastroretentive controlled release pharmaceutical dosage forms |
| DE10101307A1 (de) | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
| US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| SI1799196T1 (sl) | 2004-10-08 | 2016-10-28 | Forward Pharma A/S | Farmacevtski sestavki z nadzorovanim sproščanjem, obsegajoči ester fumarne kisline |
| DK2997953T3 (en) * | 2006-01-18 | 2019-04-15 | Intec Pharma Ltd | ADMINISTRATION ORAL ADMINISTRATION |
| DK2276473T3 (en) * | 2008-04-18 | 2017-01-09 | Intec Pharma Ltd | GASTRORETENTIV drug TO carbidopa / levodopa |
| EP2564839B1 (en) * | 2009-01-09 | 2016-05-11 | Forward Pharma A/S | Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix |
| EP2379062A1 (en) * | 2009-01-09 | 2011-10-26 | Forward Pharma A/S | Pharmaceutical composition comprising one or more fumaric acid esters |
| PE20141639A1 (es) * | 2011-06-08 | 2014-11-08 | Biogen Idec Inc | Proceso para preparar fumarato de dimetilo de alta pureza y cristalino |
| RU2014125430A (ru) * | 2011-11-24 | 2015-12-27 | Синтон Бв | Контролируемое высвобождение частиц, содержащих диметилфумарат |
| CA2862885C (en) * | 2012-02-07 | 2020-06-02 | Biogen Ma Inc. | Pharmaceutical compositions containing dimethyl fumarate |
| US20150079180A1 (en) * | 2013-09-18 | 2015-03-19 | Xenoport, Inc. | Nanoparticle compositions of dimethyl fumarate |
| IN2013MU03070A (enExample) * | 2013-09-25 | 2015-07-17 | Glenmark Pharmaceuticals Ltd | |
| US10172794B2 (en) | 2013-12-13 | 2019-01-08 | Biogen Ma Inc. | Controlled release dosage form for once daily administration of dimethyl fumarate |
| CA2939990C (en) * | 2014-02-28 | 2018-07-10 | Banner Life Sciences Llc | Controlled release enteric soft capsules of fumarate esters |
-
2016
- 2016-06-15 EA EA201890068A patent/EA201890068A1/ru unknown
- 2016-06-15 MA MA042196A patent/MA42196A/fr unknown
- 2016-06-15 CN CN201680047251.2A patent/CN107920997A/zh active Pending
- 2016-06-15 HK HK18113117.1A patent/HK1254054A1/zh unknown
- 2016-06-15 US US15/737,011 patent/US11291642B2/en not_active Expired - Fee Related
- 2016-06-15 MX MX2017016509A patent/MX387092B/es unknown
- 2016-06-15 AU AU2016279997A patent/AU2016279997B2/en not_active Ceased
- 2016-06-15 JP JP2017565133A patent/JP2018517735A/ja active Pending
- 2016-06-15 KR KR1020187001091A patent/KR20180018711A/ko not_active Ceased
- 2016-06-15 WO PCT/US2016/037486 patent/WO2016205270A1/en not_active Ceased
- 2016-06-15 EP EP16733793.0A patent/EP3310341A1/en not_active Withdrawn
- 2016-06-15 CA CA2989581A patent/CA2989581A1/en active Pending
-
2017
- 2017-12-13 IL IL256296A patent/IL256296A/en unknown
-
2021
- 2021-11-12 JP JP2021184469A patent/JP2022042512A/ja active Pending
-
2022
- 2022-01-12 AU AU2022200155A patent/AU2022200155A1/en not_active Abandoned
- 2022-02-22 US US17/677,204 patent/US20220362195A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180018711A (ko) | 2018-02-21 |
| WO2016205270A1 (en) | 2016-12-22 |
| EA201890068A1 (ru) | 2018-09-28 |
| AU2016279997A1 (en) | 2018-01-18 |
| JP2022042512A (ja) | 2022-03-14 |
| CA2989581A1 (en) | 2016-12-22 |
| MA42196A (fr) | 2018-04-25 |
| CN107920997A (zh) | 2018-04-17 |
| US11291642B2 (en) | 2022-04-05 |
| US20220362195A1 (en) | 2022-11-17 |
| JP2018517735A (ja) | 2018-07-05 |
| US20190070143A1 (en) | 2019-03-07 |
| AU2016279997B2 (en) | 2021-10-21 |
| IL256296A (en) | 2018-02-28 |
| AU2022200155A1 (en) | 2022-02-10 |
| EP3310341A1 (en) | 2018-04-25 |
| MX2017016509A (es) | 2018-08-16 |
| WO2016205270A8 (en) | 2017-01-19 |
| HK1254054A1 (zh) | 2019-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1254054A1 (zh) | 富马酸二甲酯颗粒和其药物组合物 | |
| EP3601291B1 (en) | 11,13-Modified Saxitoxins for the Treatment of Pain | |
| PH12018501281A1 (en) | Human immunodeficiency virus neutralizing antibodies | |
| IL295609B1 (en) | Hemisulfate nucleotide salt for treatment of hepatitis c virus | |
| PH12016501873A1 (en) | Anti-influenza b virus hemagglutinin antibodies and methods of use | |
| MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
| EP3506944A4 (en) | COMPOSITIONS AND METHODS FOR TREATING TUMOR SUPPRESSOR-DEFICIENT CANCER | |
| EP3302977C0 (en) | COATING DEVICE | |
| EP3328333A4 (en) | SYSTEMS AND METHODS FOR CORNEAL IMPLANTS | |
| EA201991431A1 (ru) | УСИЛЕННЫЙ ОПОСРЕДОВАННЫЙ ТРАНСПОЗОНАМИ СЕМЕЙСТВА hAT ПЕРЕНОС ГЕНОВ И АССОЦИИРОВАННЫЕ КОМПОЗИЦИИ, СИСТЕМЫ И СПОСОБЫ | |
| EP3697915A4 (en) | ADENO-ASSOCIATED VIRUS VECTOR ADMINISTRATION OF MUSCLE SPECIFIC MICRODYSTROPHIN FOR THE TREATMENT OF MUSCLE DYSTROPHY | |
| EP3673899C0 (en) | NASAL POWDER FORMULATION FOR THE TREATMENT OF HYPOGLYCEMIA | |
| EP3630102C0 (en) | FORMULATIONS FOR THE TREATMENT OF POST-TRAUMATIC STRESS DISORDER | |
| EP3645492C0 (en) | Preparation process of ortho alkoxy bisphenol monomers | |
| MX383931B (es) | Compuestos de aza-piridona y usos de estos. | |
| UA117779C2 (uk) | Піразини як модулятори gpr6 | |
| MA42423A (fr) | Procédé de préparation d'un revêtement | |
| EP3687940A4 (en) | SELF-ASSEMBLY PROCESS FOR THE MANUFACTURE OF IGEL-SHAPED PARTICLES | |
| EP3562937A4 (en) | GENE THERAPY TO TREAT MUCOPOLYSACCHARIDOSIS TYPE II | |
| EP3493823C0 (en) | POSTBIOTIC BASED COMPOUND FOR THE TREATMENT OF OCULAR INFLAMMATION | |
| HUE051948T2 (hu) | Protokollok és eljárások sclerosis multiplex kezelésére ofatumumab alkalmazásával | |
| EA201891803A1 (ru) | Фармацевтические составы в форме гранул, содержащие диметилфумарат | |
| EP3426807A4 (en) | METHOD OF METAL COATING | |
| IL282120A (en) | Buprenorphine to treat respiratory depression | |
| EP3318614A4 (en) | COATING AND SEALANT SURFACE-TREATED MEDICAL INSTRUMENT |